MLTXMoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress...

Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ, following last week’s resilience in tech and AI-linked names.

Iran’s “multipage” response reportedly included opening the Hormuz Strait prior to making nuclear concessions, while also agreeing to export some of its highly enriched uranium to a third country.

The company plans to submit its biologics license application (BLA) by September.

MoonLake Immunotherapeutics (NASDAQ:MLTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-moonlake-immunotherapeutics-stock...

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average rating of "Hold" by the sixteen brokerages that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold r...

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) saw a large decrease in short interest in April. As of April 15th, there was short interest totaling 6,654,522 shares, a decrease of 14.2% from the March 31st total of 7,757,169 shares. Based on an average daily trading volume, of...

Key PointsCEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share...

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 51,873 shares of the company's stock in a transaction dated Monday, April 13th. The shares were sold at an...